Ion Beam Applications (IBA) has secured a contract with MD Anderson Cancer Center to upgrade its proton therapy systems, marking a significant advancement in cancer treatment infrastructure. The agreement, effective January 18, 2026, includes delivery and installation of advanced beam delivery technology aimed at improving precision and patient outcomes.
The project involves retrofitting existing proton therapy facilities with IBA’s latest proton beam control systems, including enhanced imaging and real-time tumor tracking. While financial terms were not disclosed, the contract is expected to contribute to IBA’s revenue in Q1 2026. IBA shares rose 3.2% in pre-market trading following the announcement. MD Anderson, based in Houston, Texas, is one of the leading cancer centers in the U.S., underscoring the strategic importance of the deal.
The project involves retrofitting existing proton therapy facilities with IBA’s latest proton beam control systems, including enhanced imaging and real-time tumor tracking. While financial terms were not disclosed, the contract is expected to contribute to IBA’s revenue in Q1 2026. IBA shares rose 3.2% in pre-market trading following the announcement. MD Anderson, based in Houston, Texas, is one of the leading cancer centers in the U.S., underscoring the strategic importance of the deal.